Combipatch Transdermal Patch - Biweekly 0.05-0.14Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

CombiPatch: Transdermal patch - Biweekly (0.05-0.14mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png
Combipatch 50/140 Patch
Drug Image file default-drug-image.png
Combipatch 50/140 Patch

What is this Medicine?

ESTRADIOL; NORETHINDRONE (es tra DYE ole; nor eth IN drone) contains a mixture of female hormones. This medicine helps to relieve the symptoms of menopause like hot flashes, night sweats, mood changes, and vaginal dryness and irritation. It is also used to treat women with low estrogen levels or those who have had their ovaries removed.

CVS Pharmacy Patient Statistics for CombiPatch: Transdermal patch - Biweekly(0.05-0.14mg)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information
Select a Medication

Combipatch 50/140 Transdermal System

NDC: 000780377
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Menopause, Hot Flashes, Oophorectomy, Hypogonadism, Atrophic Vaginitis, Ovarian Failure

Storage Information
Protect from extreme heat
Do not store outside of the sealed pouch
Product should be used within 6 months after opening
May be stored at a temperature not exceeding 77 degrees F after first use
Prior to dispensing, store in refrigerator (36 to 46 degrees F)
Combipatch 50/140 Transdermal System

Reported Side Effects for Combipatch 50/140 Transdermal System

Endometrial Hyperplasia Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Emotional Lability Incidence:
1.0-6.0%*
Severity: MILD
Onset: EARLY
Fluid Retention Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Increase In Breast Size Incidence:
2.0-7.0%*
Severity: MILD
Onset: DELAYED
Heavy Menstrual Period Incidence:
2.0-5.0%*
Severity: MILD
Onset: DELAYED
Skin Irritation Incidence:
2.0-23.0%*
Severity: MILD
Onset: EARLY
Breakthrough Bleeding Incidence:
3.0-26.0%*
Severity: MILD
Onset: DELAYED
Inability To Sleep Incidence:
3.0-8.0%*
Severity: MILD
Onset: EARLY
Depression Incidence:
3.0-9.0%*
Severity: MODERATE
Onset: DELAYED
Nervousness Incidence:
3.0-6.0%*
Severity: MILD
Onset: DELAYED
Loose Stools Incidence:
4.0-14.0%*
Severity: MILD
Onset: EARLY
Acne Incidence:
4.0-5.0%*
Severity: MILD
Onset: DELAYED
Skin Rash Incidence:
5.0-6.0%*
Severity: MILD
Onset: EARLY
Lightheadedness Incidence:
6.0-7.0%*
Severity: MILD
Onset: EARLY
Fluid Retention Incidence:
6.0%*
Severity: MODERATE
Onset: DELAYED
Stomach Pain Incidence:
6.0-14.0%*
Severity: MILD
Onset: EARLY
Vaginal Infection Incidence:
6.0-13.0%*
Severity: MODERATE
Onset: DELAYED
Joint Pain Incidence:
6.0%*
Severity: MILD
Onset: DELAYED
Weakness Incidence:
8.0-13.0%*
Severity: MILD
Onset: DELAYED
Upset Stomach Incidence:
8.0-12.0%*
Severity: MILD
Onset: EARLY
Back Pain Incidence:
9.0-15.0%*
Severity: MILD
Onset: DELAYED
Weight Gain Incidence:
9.0%*
Severity: MILD
Onset: DELAYED
Headache Incidence:
17.0-25.0%*
Severity: MILD
Onset: EARLY
Menstrual Cramps Incidence:
20.0-31.0%*
Severity: MILD
Onset: DELAYED
Breast Pain Incidence:
25.0-48.0%*
Severity: MILD
Onset: DELAYED
No Menstrual Periods Incidence:
54.0-65.0%*
Severity: MILD
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Combipatch 50/140 Transdermal System

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Minor Lifestyle Interaction
Grapefruit juice and Combipatch 50/140 Transdermal System(Estradiol)
Grapefruit juice and Estrogens(Estradiol)
Grapefruit juice and grapefruit-containing foods may increase the side effects of estrogen in some females, such as nausea, breast tenderness, headache or fluid retention. There may be no interaction. Do not significantly change your grapefruit intake while taking estrogens for hormone replacement therapy or as part of hormonal birth control products. Report any unusual side effects, like unusual non-menstrual vaginal bleeding, promptly for evaluation.
Pregnancy & Lactation Information
FIRST Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

SECOND Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

THIRD Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with CombiPatch

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.